Search the GHTC website

Global health R&D delivers for Rhode Island

US government investment in global health R&D has delivered

$80.1 million
to Rhode Island research institutions
850+ new jobs
for Rhode Island
Rhode Island's top USG-funded global health R&D institutions

Rhode Island's top USG-funded global health R&D institutions

Brown University
$29.4 million
Rhode Island Hospital
$22 million
University of Rhode Island
$11.5 million
Miriam Hospital
$8.9 million
Women & Infants Hospital-Rhode Island
$7 million
$1.3 million
Gordon Research Conferences
$76 thousand

Rhode Island's top areas of global health R&D by USG funding

Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Diarrheal diseases
Filoviral diseases (including Ebola, Marburg)
Hepatitis C
Multi-disease/health area R&D
Global health R&D at work in Rhode Island

Rhode Island Hospital’s Center for International Health Research (CIHR) is working on solutions to two of the world’s most devastating parasitic diseases. Of all parasitic infections, malaria is the leading killer. Efforts at CIHR, in partnership with Brown University, have yielded vaccine candidates that are now in the development pipeline. Second only to malaria is schistosomiasis, an infection of flatworms that damages human organs and impairs development in children. While this neglected tropical disease can be treated, a vaccine is badly needed. CIHR and partners have developed a vaccine candidate that works in mice and is showing promise in water buffalo, a major transmitter.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID/NIH